Spago Nanomedical Publishes Scientific Paper on Positive Preclinical Files with Tumorad(R) as Therapy of Solid Tumors

LUND, SE / ACCESSWIRE / January 10, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) this day announced the publication of data on the composition, stability, and mode of action for its main candidate drug 177Lu-SN201. The preclinical results reveals that the candidate drug accumulates favorably in tumors, inhibits tumor growth, presents prolonged survival when put next to help an eye on, and is ethical for systemic therapy of cancer. The paper became once printed within the scientific journal ACS Omega.

“The want for more vivid the exact technique to treat metastatic and aggressive cancer stays indispensable. Spago Nanomedical´s candidate drug 177Lu-SN201 belongs to a brand fresh generation of focused radionuclide therapies that presents different for precision therapy of cancer, as monotherapy or in aggregate with replacement therapies. The printed results present extra toughen for the beginning of clinical building within the Tumorad mission”, says CEO Mats Hansen.

The paper, titled “Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Therapy”, became once printed within the uncover reviewed scientific journal ASC Omega. The outcomes reveals that the candidate drug accumulates favorably in tumors and is ethical for systemic therapy of cancer.

Therapy with 177Lu-SN201 inhibited tumor growth and resulted in 37% longer survival when put next to the help an eye on community in a preclinical mannequin of colon cancer. The relative accumulation of 177Lu-SN201 in tumor, analyzed by single-photon emission computed tomography (SPECT), became once 19.4% of the injected dose per gram tumor tissue. This is a limited bit greater than has been previously reported for the Novartis drug Lutathera, a radionuclide therapy well-liked by the EMA and the FDA for therapy of sufferers with neuroendocrine tumors.

Outdated preclinical results from regulatory evaluate reveals factual security of the nanoparticle SN201 in doses that broadly exceeds the anticipated clinical dose. In summary, results stamp that 177Lu-SN201 is a promising fresh radionuclide therapy for physiological focusing on and tumor selective therapy of cancer with capacity expend in different replacement tumor varieties. Preparations for clinical trials proceeds in accordance with thought and the aim is to start a allotment 1/2a trial in cancer sufferers inside quickly.

The paper is on hand for downloading throughout the following link:


For added records, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, [email protected]

Spago Nanomedical AB is a Swedish nanomedicines firm in clinical building allotment. The firm´s building projects are in accordance with a platform of polymeric presents with inviting properties for more valid diagnosis and therapy of life-threatening and debilitating ailments. Spago Nanomedical´s half is listed on Nasdaq First North Development Market (ticker: SPAGO). For added records, witness www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the firm.


Spago Nanomedical publishes scientific paper on obvious preclinical records with Tumorad® as therapy of stable tumors

SOURCE: Spago Nanomedical

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button